Gabon is moving to protect a slow-growing central African rainforest shrub whose root bark has long anchored several of the country's ritual traditions, as US drug companies increasingly look to its psychoactive properties for treating addiction and some mental illnesses. The plant, Tabernanthe iboga, is the source of a bitter root bark that worshippers swallow during night-long ceremonies held in temples lit by candles and sheltered by palm fronds.
The concern in Gabon is that growing international interest in iboga's therapeutic potential could lead to overharvesting of a species that regenerates slowly in the wild, and to the patenting or commercial control of knowledge that local communities regard as sacred. The plant's reputation has drawn comparisons with ayahuasca, the Amazonian brew that became a global wellness phenomenon and a target for pharmaceutical research.
Iboga's root bark contains ibogaine, a compound that has attracted scientific attention for its effects on addiction and trauma. Researchers and clinicians have studied it as a possible treatment for substance dependence, and the plant's ceremonial use in Gabon is described as central to rituals that participants believe can address addiction and psychological distress.
The stakes extend beyond pharmacology. For Gabonese practitioners, iboga is not merely a raw material but a cornerstone of spiritual and community life, and its harvesting and use are governed by customary rules. Officials and advocates argue that any commercial development should be negotiated with the communities that have stewarded the plant, and that wild populations need protection before demand outpaces supply.
The species grows slowly, which makes it especially vulnerable to intensive collection. Unlike fast-cycling crops, a rainforest shrub that takes years to mature cannot easily absorb a surge in demand, and conservationists warn that unregulated harvesting could threaten both the plant and the traditions that depend on it.
The comparison with ayahuasca is instructive. That brew moved from Amazonian ceremony to international retreats and clinical trials, generating both economic opportunity and disputes over biopiracy and benefit-sharing. Gabon's effort to set rules now reflects a broader push by source countries to assert control over genetic resources and traditional knowledge before foreign firms file patents or scale up extraction.
For US drug companies, iboga represents a promising avenue in a field where effective addiction treatments remain limited. But the path from rainforest shrub to regulated medicine runs through questions of supply, sustainability, consent and compensation, all of which Gabonese officials are now trying to settle on their own terms.
The outcome will shape not only the future of a single plant but also the template for how traditional knowledge travels from ritual settings into laboratories and markets. Gabon's position is that protection and research can coexist, provided the communities who hold iboga sacred remain part of the decision.
9
